TY - JOUR
T1 - Philadelphia-like acute lymphoblastic leukemia
T2 - diagnostic dilemma and management perspectives
AU - Kotb, Ahmed
AU - El Fakih, Riad
AU - Hanbali, Amr
AU - Hawsawi, Yousef
AU - Alfraih, Feras
AU - Hashmi, Shahrukh
AU - Aljurf, Mahmoud
N1 - Publisher Copyright:
© 2018 ISEH – Society for Hematology and Stem Cells
PY - 2018/11
Y1 - 2018/11
N2 - Acute lymphoblastic leukemia (ALL) is an aggressive hematologic malignancy characterized by suboptimal outcomes in the adult age group. Recently, a new subtype called Philadelphia (Ph)-like ALL has been described. This subgroup is characterized by high cytokine receptor and tyrosine kinase signaling expression, resulting in kinase activation through stimulation of two main pathways, the ABL and JAK/STAT pathways. The diagnostic method or approach for Ph-like ALL is still not standardized and efforts are ongoing to identify an easy and applicable diagnostic method. Accurate and standard testing approaches are much needed and this will facilitate better understanding of this subgroup, including better estimation of the prevalence and incidence in different age groups and the clinical outcomes of such new entity. Here, we review the currently available diagnostic tools, activated pathways, and different therapeutic approaches used to target this subgroup.
AB - Acute lymphoblastic leukemia (ALL) is an aggressive hematologic malignancy characterized by suboptimal outcomes in the adult age group. Recently, a new subtype called Philadelphia (Ph)-like ALL has been described. This subgroup is characterized by high cytokine receptor and tyrosine kinase signaling expression, resulting in kinase activation through stimulation of two main pathways, the ABL and JAK/STAT pathways. The diagnostic method or approach for Ph-like ALL is still not standardized and efforts are ongoing to identify an easy and applicable diagnostic method. Accurate and standard testing approaches are much needed and this will facilitate better understanding of this subgroup, including better estimation of the prevalence and incidence in different age groups and the clinical outcomes of such new entity. Here, we review the currently available diagnostic tools, activated pathways, and different therapeutic approaches used to target this subgroup.
UR - http://www.scopus.com/inward/record.url?scp=85053034316&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053034316&partnerID=8YFLogxK
U2 - 10.1016/j.exphem.2018.07.007
DO - 10.1016/j.exphem.2018.07.007
M3 - Review article
C2 - 30075295
AN - SCOPUS:85053034316
SN - 0301-472X
VL - 67
SP - 1
EP - 9
JO - Experimental Hematology
JF - Experimental Hematology
ER -